University Hospital Regensburg
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 4.9K
- Market Cap
- -
Clinical Trials
25
Active:5
Completed:11
Trial Phases
4 Phases
Phase 1:1
Phase 2:3
Phase 4:2
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Not Applicable
4 (40.0%)Phase 2
3 (30.0%)Phase 4
2 (20.0%)Phase 1
1 (10.0%)Integrated Analysis of Therapy Response and Resistence in Embryonal Tumors and Gliomas
Not yet recruiting
- Conditions
- Embryonal TumorGlioma, MalignantMedulloblastomaEpendymoma
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- University Hospital Regensburg
- Target Recruit Count
- 72
- Registration Number
- NCT06323408
Impact of Surgical Mask, FFP2 Mask and FFP3 Mask (With and Without Exhalation Valve) on Exercise Tolerance and Blood Gas Parameters of Patients With Known Lung Disease and Long-term Oxygen Therapy
Completed
- Conditions
- Longterm Oxygen TherapyFace Mask
- First Posted Date
- 2023-07-05
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- University Hospital Regensburg
- Target Recruit Count
- 72
- Registration Number
- NCT05931016
- Locations
- 🇩🇪
Klinik Donaustauf, Donaustauf, Bavaria, Germany
Investigating the Equivalence of the EORTC QLQ-C30 and the QLQ-F17
Completed
- Conditions
- Quality of LifeCancer
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- University Hospital Regensburg
- Target Recruit Count
- 2672
- Registration Number
- NCT05479682
- Locations
- 🇩🇪
Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany
Impact of Bevacizumab on Symptom Burden and Neurological Deficits in Patients With Recurrent Glioblastoma
Completed
- Conditions
- AngiogenesisGlioblastoma
- First Posted Date
- 2021-07-23
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- University Hospital Regensburg
- Target Recruit Count
- 203
- Registration Number
- NCT04974983
- Locations
- 🇩🇪
University Hospital Regensburg, Regensburg, Germany
Systematic Assessment of Self-help Tools for the Management of Chronic Tinnitus
Not Applicable
- Conditions
- Tinnitus, Subjective
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- University Hospital Regensburg
- Target Recruit Count
- 50
- Registration Number
- NCT04069364
- Locations
- 🇩🇪
University of Regensburg, Regensburg, Germany
- Prev
- 1
- 2
- 3
- 4
- Next
News
Axatilimab Approved for Chronic GVHD After Failure of Two Prior Therapies
Axatilimab has received FDA approval for treating chronic graft-versus-host disease (GVHD) in patients who have not responded to at least two prior systemic therapies.